AVLN Avalyn Pharma Inc. - common stock
$40.03
Price · Aug 19, 2026
Fundamentals as of Aug 12, 2026
52W Range
$24–$40
99% of range
Analyst Rating
BUY
10 analysts
Price Target
$60
+50% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
AVLN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$40.03
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$24 – $40
AVLN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
AVLN
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
AVLN
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
AVLN
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
AVLN
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
AVLN
Peer Median
AVLN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
10 analysts
- Strong Buy 4 40.0%
- Buy 5 50.0%
- Hold 1 10.0%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
4 analysts · 2026-08-17
Median
$54.50
Mean
$60.00
← Below all targets
$40.03
Low
$51.00
High
$80.00
Median target
$54.50
+36.1%
Mean target
$60.00
+49.9%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| AVLN | — | — | — | — | — | — |
| SEPN | $1.25B | -25.3 | 4174.5% | -106.4% | -12.9% | — |
| TRLV | — | — | -0.45% | -10.3% | -10.4% | 60.2% |
| ANIP | $1.78B | 23.8 | 43.8% | 8.9% | 16.6% | — |
| ETON | $457M | — | 104.9% | -5.8% | -18.4% | 53.5% |
| MAZE | $2.04B | -13.6 | — | — | -598.9% | — |
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| LBRX | $563M | -7.1 | — | — | -25.5% | — |
| INVA | — | 6.1 | 14.7% | — | — | — |
| XERS | $1.30B | — | 43.7% | 0.19% | -19.7% | — |
| PAHC | — | 21.5 | 27.4% | 3.7% | 17.8% | 30.9% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 20
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $52M | |
| Short-term Investments | $86M | |
| Prepaid Expense | $5M | |
| Current Assets | $144M | |
| PP&E (Net) | $792.0K | |
| PP&E (Gross) | $846.0K | |
| Accum. Depreciation | $54.0K | |
| Other Non-current Assets | $3M | |
| Total Assets | $149M | |
| Accounts Payable | $4M | |
| Accrued Liabilities | $10M | |
| Current Liabilities | $14M | |
| Capital Leases | $1M | |
| Total Liabilities | $15M | |
| Common Stock | $24.0K | |
| Retained Earnings | $-265M | |
| AOCI | $134.0K | |
| Stockholders' Equity | $-239M | |
| Liabilities + Equity | $149M | |
| Shares Outstanding | 1,227,186 |
Income Statement 13
| Metric | Trend | Q2 2026 | Q1 2026 | Q1 2025 |
|---|---|---|---|---|
| R&D Expense | $25M | $23M | $15M | |
| SG&A Expense | $7M | $5M | $3M | |
| Operating Expenses | $31M | $28M | $19M | |
| Operating Income | $-31M | $-28M | $-19M | |
| Interest Income | $3M | $1M | $1M | |
| Other Non-op | $-69.0K | $13.0K | $-35.0K | |
| Income Tax | $0 | $0 | $0 | |
| Net Income | $-29M | $-27M | $-18M | |
| EPS (Basic) | $-0.98 | $-21.83 | $-63.24 | |
| EPS (Diluted) | $-0.98 | $-21.83 | $-63.24 | |
| Shares (Basic) | 29,650,660 | 1,230,698 | 276,792 | |
| Shares (Diluted) | 29,650,660 | 1,230,698 | 276,792 | |
| EBITDA | $-31M | $-28M | · |
Balance Sheet 22
| Metric | Trend | Q2 2026 | Q1 2026 | Q1 2025 |
|---|---|---|---|---|
| Cash & Equivalents | $264M | $92M | · | |
| Short-term Investments | $88M | $31M | · | |
| Prepaid Expense | $6M | $7M | · | |
| Current Assets | $358M | $130M | · | |
| PP&E (Net) | $1M | $1M | · | |
| PP&E (Gross) | $1M | $1M | · | |
| Accum. Depreciation | $216.0K | $117.0K | · | |
| Other Non-current Assets | $3M | $3M | · | |
| Total Assets | $425M | $136M | · | |
| Accounts Payable | $3M | $3M | · | |
| Accrued Liabilities | $7M | $8M | · | |
| Current Liabilities | $11M | $12M | · | |
| Capital Leases | $1M | $1M | · | |
| Total Liabilities | $27M | $28M | · | |
| Long-term Debt | $15M | $15M | · | |
| Total Debt | $15M | $15M | · | |
| Common Stock | $67.0K | $24.0K | · | |
| Retained Earnings | $-321M | $-292M | · | |
| AOCI | $-95.0K | $12.0K | · | |
| Stockholders' Equity | $398M | $-264M | · | |
| Liabilities + Equity | $425M | $136M | · | |
| Shares Outstanding | 44,333,094 | 1,232,442 | · |
Cash Flow 8
| Metric | Trend | Q2 2026 | Q1 2026 | Q1 2025 |
|---|---|---|---|---|
| Stock-based Comp | $3M | $1M | $543.0K | |
| Operating Cash Flow | $-26M | $-30M | $-19M | |
| CapEx | $269.0K | $318.0K | $8.0K | |
| Investing Cash Flow | $-119M | $55M | $24M | |
| Stock Issued | · | $50M | · | |
| Net Stock Activity | · | $50M | · | |
| Financing Cash Flow | $317M | $15M | $0 | |
| Free Cash Flow | · | $-30M | · |
Profitability 2
| Metric | Trend | Q2 2026 | Q1 2026 | Q1 2025 |
|---|---|---|---|---|
| ROA | -13.6% | -39.6% | · | |
| ROE | -14.5% | 20.3% | · |
Liquidity & Solvency 4
| Metric | Trend | Q2 2026 | Q1 2026 | Q1 2025 |
|---|---|---|---|---|
| Current Ratio | 33.1 | 11.0 | · | |
| Quick Ratio | 32.6 | 10.4 | · | |
| Debt / Equity | 0.0 | -0.1 | · | |
| LT Debt / Equity | 0.0 | -0.1 | · |
Valuation (TTM) 5
| Metric | Trend | Q2 2026 | Q1 2026 | Q1 2025 |
|---|---|---|---|---|
| Market Cap | $1.46B | · | · | |
| Enterprise Value | $1.12B | · | · | |
| P/B | 3.7 | · | · | |
| P / Tangible Book | 3.7 | · | · | |
| EV / EBITDA | -35.9 | · | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Company insiders 13 insiders · 5 officers · 6 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Lyn Baranowski | Chief Executive Officer | April 29, 2026 A | — | 0 | 0 | $0 |
| Douglas R Carlson | Chief Financial Officer | April 30, 2026 A | — | 0 | 0 | $0 |
| Melissa Rhodes | Chief Operating Officer | April 29, 2026 A | — | 0 | 0 | $0 |
| Adam H. Golden | General Counsel | April 29, 2026 A | — | 0 | 0 | $0 |
| Howard Lazarus | Chief Medical Officer | April 29, 2026 A | — | 0 | 0 | $0 |
| Jill Carroll | Director | May 1, 2026 C | 2,186,562 | 1 | 0 | $5,000,004 |
| Erin Lavelle | Director | April 30, 2026 A | — | 0 | 0 | $0 |
| Kate Haviland | Director | April 29, 2026 A | — | 0 | 0 | $0 |
| Jon Congleton | Director | April 29, 2026 A | — | 0 | 0 | $0 |
| Heather D Turner | Director | April 29, 2026 A | — | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% owner | May 1, 2026 C | 1,275,486 | 0 | 0 | $0 |
| FMR LLC | 10% owner | May 1, 2026 C | 2,284,535 | 0 | 0 | $0 |
| Novo Holdings A/S | — | May 1, 2026 C | 3,883,289 | 1 | 0 | $9,999,990 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| SR One Capital Management, LLC, SR One Capital Fund II Aggregator, LP, SR One Capital Partners II, LP, AMZL, LP, SR One Capital SMA Partners, LP, Simeon George | May 8, 2026 | 7.50% | Initial filing | Passive investment | SEC |
| SUVRETTA CAPITAL MANAGEMENT, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., Aaron Cowen | May 8, 2026 | 5.60% | Initial filing | Board campaign | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 14 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.03% | 2,423 SH | Aug. 8, 2026 | Daily |
| IWO · iShares Trust | 0.02% | 108,087 SH | Aug. 8, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 98,545 SH | Aug. 8, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.02% | 12,713 SH | Aug. 8, 2026 | Daily |
| IWM · iShares Trust | 0.02% | 426,636 SH | Aug. 8, 2026 | Daily |
| IWN · iShares Trust | 0.01% | 48,610 SH | Aug. 8, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 192,602 SH | Aug. 8, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 4,638 SH | Aug. 8, 2026 | Daily |
| BNDX · VANGUARD CHARLOTTE FUNDS | 0.01% | 16,035,000 PA | Aug. 8, 2026 | Daily |
| ISCB · iShares Trust | 0.01% | 852 SH | Aug. 8, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 6,674 SH | Aug. 8, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 534,440 SH | Aug. 8, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 1,442 SH | Aug. 8, 2026 | Daily |
| BNDW · VANGUARD SCOTTSDALE FUNDS | 0.00% | 120,332 PA | Aug. 8, 2026 | Daily |